US biotech BioAge Labs (Nasdaq: BIOA) is expanding its obesity pipeline just months after shelving its lead drug in the ...

Bioage Labs Inc. is advancing its apelin receptor (APJ) agonist programs for obesity and other indications, and has entered ...

Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

Scientists from La Trobe University and Phillipps-University of Marburg (Germany) have discovered how a peptide called Apelin regulates blood vessel growth, opening new avenues of research for ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. The adipokine apelin has been directly ...

Two months after going public, BioAge stopped a phase 2 trial of its oral apelin receptor agonist azelaprag. Investors fled, but the biotech left the door open, noting that it remained encouraged ...

Basking in the glow of a collaboration involving Eli Lilly’s diabetes/weight loss blockbuster tirzepatide, BioAge Labs has completed an oversubscribed $170 million Series D financing, the ...

Azelaprag mimics the activity of apelin, an “exerkine” peptide that is released in response to exercise. Apelin acts on skeletal muscle, heart, and central nervous system to regulate ...